RXRX
Recursion Pharmaceuticals Inc.
$5.52
-$0.13(-2.30%)
50
Overall
60
Value
41
Tech
--
Quality
Market Cap
$2.54B
Volume
43.30M
52W Range
$3.79 - $12.36
Target Price
$6.47
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $10.2M | $39.8M | $44.6M | $58.8M | ||
| Total Revenue | $10.2M | $39.7M | $44.6M | $58.5M | ||
| COST OF GOODS SOLD | ||||||
| Cost of Revenue | -- | $48.3M | $42.6M | $45.2M | ||
| GROSS PROFIT | ||||||
| Gross Profit | $10.2M | $-8.6M | $2.0M | $13.3M | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $193.0M | $237.1M | $352.0M | $492.6M | ||
| Research & Development | $135.3M | $155.7M | $241.2M | $314.4M | ||
| Research Expense | $135.3M | $155.7M | $241.2M | $314.4M | ||
| Selling, General & Administrative | $57.7M | $81.6M | $110.8M | $178.2M | ||
| General & Administrative Expenses | $57.7M | $81.6M | $110.8M | $178.2M | ||
| Salaries & Wages | -- | $26.9M | $51.7M | $79.5M | ||
| Depreciation & Amortization | $8.8M | $11.4M | $24.4M | $36.5M | ||
| Depreciation & Amortization | $8.8M | $11.4M | $24.4M | $36.5M | ||
| Amortization | $1.4M | $1.3M | $52.1M | $339.9M | ||
| Other Operating Expenses | -- | $-818.0K | $-1.7M | $-1.5M | ||
| OPERATING INCOME | ||||||
| Operating income | $-182.8M | $-245.7M | $-350.1M | $-479.0M | ||
| EBITDA | $-175.1M | $-288.9M | $-307.7M | $-426.8M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | $3.0M | $55.0K | $97.0K | $1.5M | ||
| Net Non-Operating Interest Income/Expense | $-2.9M | $6.2M | $19.0M | $14.2M | ||
| Gain on Sale of Securities | $73.0K | $6.3M | $19.1M | $15.8M | ||
| Other Income/Expense | $3.7M | $52.0K | $-17.9M | $-14.2M | ||
| Other Special Charges | $-3.7M | $6.3M | $17.9M | $14.2M | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-183.5M | $-300.6M | $-332.1M | $-463.3M | ||
| Pre-Tax Income | $-186.5M | $-239.5M | $-332.1M | $-464.8M | ||
| INCOME TAX | ||||||
| Tax Provision | $-46.6M | $-61.2M | $-4.1M | $-1.1M | ||
| NET INCOME | ||||||
| Net Income | $-186.5M | $-239.5M | $-328.1M | $-463.7M | ||
| Net Income (Continuing Operations) | $-186.5M | $-239.5M | $-328.1M | $-463.7M | ||
| Net Income (Discontinued Operations) | $-186.5M | $-239.5M | $-328.1M | $-463.7M | ||
| Net Income (Common Stockholders) | $-186.5M | $-239.5M | $-328.1M | $-463.7M | ||
| Normalized Income | -- | -- | -- | $-465.9M | ||
| TOTALS | ||||||
| Total Expenses | $193.0M | $285.4M | $394.6M | $537.8M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $125.3M | $175.5M | $207.9M | $274.2M | ||
| Average Shares Outstanding (Diluted) | $125.3M | $175.5M | $207.9M | $274.2M | ||
| Shares Outstanding | $170.8M | $191.2M | $234.7M | $402.0M | ||
| Basic EPS | $-1.49 | $-1.36 | $-1.58 | $-1.69 | ||
| Basic EPS (Continuing Operations) | $-1.49 | $-1.36 | $-1.58 | $-1.69 | ||
| Diluted EPS | $-1.49 | $-1.36 | $-1.58 | $-1.69 | ||
| Diluted EPS (Continuing Operations) | $-1.49 | $-1.36 | $-1.58 | $-1.69 | ||
| OTHER METRICS | ||||||
| Other Gand A | $57.7M | $81.6M | $110.8M | $178.2M | ||
| Rent And Landing Fees | $6.4M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RXRX | $5.52 | -2.3% | 43.30M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Recursion Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW